To The Moon

$IX Biopharma(42C.SI)$ 0.8 Target Price. --Ix Biopharama Medical Breakthrough-- iX Biopharma achieved a major medical and commercial breakthrough with Wafermine, its patented sublingual (under-the-tongue) ketamine wafer for non-opioid acute pain management.   --The Core Technology-- WaferiXFast Absorption: Wafers dissolve sublingually in minutes, letting active ingredients enter the bloodstream directly and bypass the gut. High Bioavailability: Provides a needle-free, predictable alternative to intravenous  infusions or standard oral pills. Drug Repurposing: Applies the delivery system to central nervous system agents and other urgent indications.  --Key Pipeline & Commercial Milestones-- Backed by a US$40.95 million cont

$PanUnited(P52.SI)$ 2 Target Price. *Growth Catalysts for Pan-United Corporation (P52.SI)* Pan-United is Singapore's  largest ready-mixed concrete producer, and analysts see several drivers supporting growth into 2026-2027: 1). Singapore Construction Demand Surge - *Public sector pipeline*: New HDB developments, Cross Island Line, Tuas Mega Port, and institutional projects are expected to drive ∼55% of total construction demand. - *RMC volume growth*: Ready-mix concrete demand is projected to jump 34% from 13.4 million m³ in 2024 to 18 million m³ by 2027. - Analysts forecast EPS for Pan-United to grow 6-22% in FY26-FY27 on stronger offtake volume. *2. ESG & Low-Carbon Concrete Leadership* - Pan-United specializes in low-carbon concrete

$IX Biopharma(42C.SI)$ 0.8 Target Price. --iX Biopharma Ltd(42C) Growth Catalysts-- Shift towards commercialisation of WaferiX subligual delivery of drugs could bump up revenue by as much as 250% in FY-2026, backed by planned capacity expansion. Out-licensing of the sublingual ketamine wafer, Wafermine, for Phase 3 development will be a major catalyst and expected to turn iX Biopharma profitable in long-term.  Specialty pharmaceutical and nutraceutical drugs will benefit from the planned six-fold increase in production capacity to meet the expected surge in demand. Investment Merits Out-licensing world's first sublingual ketamine formula, Wafermine, for Phase 3 development is a near-term catalyst. Since the completion of its end-of-Ph

$REALLOYS INC(ALOY)$ $18 Target Price -- About Realloys Inc (ALOY)-- RealLoys Inc is at the centre of a major US policy push to build a domestic rare-earth supply chain, which has driven significant  bullish momentum and impact on it's defence and eletronic sector. -- Growth Catalysts for ALOY-- 1). Trump Key Minerals & Rare Earth Company in 2026-08-07 President Trump hosted 200+ mining executives and announced ~US$3 billion in federal funding for critical minerals. ALOY surged ~15% on the day, alongside the broader US rare-earth sector. Trump Public Endorsement of ALOY 2026-08-08.  In a live interview, Trump explicitly named ALOY as a core upstream supplier for the US permanent-magnet supply chain, stating it would r

$Sheng Siong(OV8.SI)$  $3.8 Target Price.  Most investors spend too much time thinking about when to buy and when to sell. But what if selling was not an option? Suppose the Singapore market closed tomorrow and stayed shut for the next 10 years. Which businesses would you still be happy to own? Warren Buffett once said investors should buy businesses they are happy to own for years, not days. The one Singapore that pass the test is as follows: Sheng Siong (SGX: OV8) – The Defensive Consumer Business Why I'd Hold It for 10 Years There are retailers who do not have to reinvent themselves to continue growing. In hard times, people are more careful about their expenses, and that is what distinguishes Sheng Siong f

$IX Biopharma(42C.SI)$ $0.8 Target Price --About IX Biopharma (42C.SI)-- iX Biopharma Ltd (SGX: 42C) is a specialty pharmaceutical and nutraceutical company focused on developing, manufacturing, and commercializing products using its proprietary sublingual drug delivery technologies. Its core growth catalysts center on commercial technology expansion, U.S. market entry, and joint venture/licensing opportunities. --Growth Catalysts for iX Biopharma-- 1). Commercialization & Out-Licensing of WaferiX®: Monetization of its patented sublingual wafer platform (WaferiX®, WaferlogiX) via out-licensing deals, tech transfers, and manufacturing agreements for repurposed pharmaceutical molecules (such as Wafermine for pain management and Wafesil f

$Hong Leong Asia(H22.SI)$ $3.8 Target Price --Growth Catalysts for Hong Leong Asia (H22.SI)-- Hong Leong Asia's key growth catalysts centre on three pillars: (1) a proposed spin-off and Hong Kong listing of a subsidiary, which could unlock significant embedded value, (2) strong operating momentum and Q1-2026 earnings from its core engine business via China Yuchai International (CYD), and (3) a healthy balance sheet supporting both organic expansion and shareholder returns. The stock trades at a modest P/S of 0.47x, suggesting the market may not be fully pricing in these catalysts. (1). Proposed Spin-Off & HK Listing of Subsidiary On 28 January 2026, Hong Leong Asia announced plans to spin off an indirect subsidiary and list it on the H

It's much cheaper to buy-in these high valued U.S stocks at SGX and also the SGD profit/loss is unaffected by the U.S Currency rate.

$QAF(Q01.SI)$ $1.2 Target Price --Overview of QAF -- QAF Limited (SGX: Q01), a regional multi-brand food player known for flagship brands like Gardenia and Cowhead, drives its operational growth through core distribution network expansion, brand power, supply chain scale, and disciplined capital allocation.   --Growth Catalysts for QAF-- 1). Dominant Market Leadership & Pricing Power (Bakery Division): As a market leader in packaged bread across Singapore, Malaysia, and the Philippines under the Gardenia banner, QAF maintains structural pricing power. Strong brand equity allows the group to pass on elevated raw material (wheat, flour) and energy costs to retail prices without severe volume destruction. 2). Expansion of D

$Sheng Siong(OV8.SI)$  $3.60 Target Price. --Overview of Sheng Siong (OV8)-- Sheng Siong Group Ltd (SGX: OV8) relies on a mix of store network expansion, operational efficiency, macro-driven demand, and new sales channels to drive its core financial performance. --Growth Catalysts for ShengSiong-- 1). Aggressive Store Expansion Pipeline: The company's primary growth engine remains physical store network expansion. Adding 16 new stores in Singapore between 2025 and 1H 2026, Sheng Siong operates 90 domestic outlets alongside 6 overseas stores in Kunming, China. Future pipeline visibility is secured through upcoming openings in new housing developments like Hougang, Rivervale, and Woodlands, alongside ongoin